Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPICI
2024-514644-93-00Phase 3Authorised
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Jul 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of pembrolizumab, axitinib, lenvatinib, cabozantinib and nivolumab in metastatic renal cell carcinoma (mRCC) (2 arms), sponsored by Centre Hospitalier Universitaire de Bordeaux. Primary endpoint: Percentage of participants without progression at 12 months after randomisation. Planned start Jul 2024; status: authorised.
02
Drugs
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on 2024-514644-93-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514644-93-00.